NOVOZYMES A/S/S (OTCMKTS:NVZMY) and Microbot Medical (NASDAQ:MBOT) are both basic materials companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.
Insider & Institutional Ownership
0.2% of NOVOZYMES A/S/S shares are owned by institutional investors. Comparatively, 14.8% of Microbot Medical shares are owned by institutional investors. 14.5% of Microbot Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares NOVOZYMES A/S/S and Microbot Medical’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|NOVOZYMES A/S/S||$2.28 billion||5.59||$511.00 million||$1.75||24.52|
|Microbot Medical||N/A||N/A||-$7.24 million||($2.41)||-2.10|
NOVOZYMES A/S/S has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than NOVOZYMES A/S/S, indicating that it is currently the more affordable of the two stocks.
NOVOZYMES A/S/S pays an annual dividend of $0.50 per share and has a dividend yield of 1.2%. Microbot Medical does not pay a dividend. NOVOZYMES A/S/S pays out 28.6% of its earnings in the form of a dividend.
Volatility & Risk
NOVOZYMES A/S/S has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 4.99, meaning that its stock price is 399% more volatile than the S&P 500.
This is a breakdown of recent ratings for NOVOZYMES A/S/S and Microbot Medical, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Microbot Medical has a consensus target price of $5.88, indicating a potential upside of 16.11%. Given Microbot Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Microbot Medical is more favorable than NOVOZYMES A/S/S.
This table compares NOVOZYMES A/S/S and Microbot Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
NOVOZYMES A/S/S beats Microbot Medical on 9 of the 15 factors compared between the two stocks.
NOVOZYMES A/S/S Company Profile
Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry. It also provides wastewater solutions, such as additives, biogas production, industrial bio cleaning, compound removal, odor control, and system start-up solutions; and textile solutions comprising bioscouring, bleach clean-up, desizing, denim finishing and abrasion, and biopolishing solutions. In addition, the company offers forest products that include bleach boosting, deinking, fiber modification, effluent control, pitch and stickies control, and starch modification products; and leather solutions, which comprise biopreparation, degreasing, and re-bating. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis; and rtrypsin for cell culture. Novozymes A/S has a strategic collaboration with Boehringer Ingelheim Animal Health for the research and development, production, marketing, and sale of a portfolio of probiotic products. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Microbot Medical Company Profile
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures. It also holds an intellectual property portfolio that comprises 9 patent families, which include 9 patents granted in the United States, 12 patents granted outside the United States, and 15 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Receive News & Ratings for NOVOZYMES A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NOVOZYMES A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.